Price: $253.44
· 1 day: -1.10% · 5 days: -0.27% · 1 month: +16.38% · YTD: -0.03%
As of 2026-11-12 21:00 UTC.
52-week range: $195.14 – $269.44 (currently at 78% of the range).
STE is in an uptrend, momentum firm. $257.04 is the level overhead; $250 the first support below.
4 of 6 technical checks lean bullish.
| Trend | Uptrend · above 50-day & 200-day |
|---|---|
| Momentum | RSI 69.7 · MACD bullish |
| Trend strength | ADX 43.4 · strong trend |
| Location | +13.9% vs 50-day MA |
| 52-week range | -6% from high · +27% from low |
| Volatility | ATR 7.19 · ~2.8%/day |
| Level | Type | Distance |
|---|---|---|
| $257.04 (resistance) | swing zone | 1.42% |
| $268.65 (resistance) | 52w high | 6.0% |
| $275.0 (resistance) | round | 8.51% |
| $250.0 (support) | round | -1.36% |
| $240.86 (support) | swing zone | -4.96% |
| $235.0 (support) | swing zone | -7.28% |
| RSI (14) | 69.68 | MACD | 9.7529 |
|---|---|---|---|
| ADX (14) | 43.4 | ATR (14) | 7.19 |
| 50-day average | $222.52 | 200-day average | $224.12 |
Next earnings: 2027-02-03. STE earnings date, time and past reactions.
Report of 2026-11-03, updated 2026-11-05.
Since the November 3 report, Steris (STE) has climbed 9.4% over five days, closing at $253.98 on November 5, while the S&P 500 fell 3.6% and XLV rose 1.9% in the same window. The move was driven by the company’s fiscal Q2 earnings on November 4, which showed revenue up 9% year-over-year and adjusted EPS of $2.94 versus $2.47, along with a raised full-year outlook (SEC EDGAR). The stock is now up 21.7% over the past month and leads both SPY and XLV over 50 days.
The picture holds. The stock remains above its 40-week average and above the swing-zone support at $251.03, which has not been tested since the report. The upside breakout level of $256.3 (swing zone) is now only 0.9% above the close, but volume on the day was 8.8% below the 20-day average, so the breakout math still falls short of a 3-to-1 reward-to-risk at the 52-week high of $268.65. The stop at $249.3 and the level that would change the picture—a weekly close below $240.86—are both unchanged. RSI at 75.4 suggests the stock is overbought, but the trend remains aligned with the weekly uptrend.
STERIS plc (STE) traded at $231.50 on November 3, 2026, down 0.8% on the day and one session before earnings. The weekly uptrend is intact and the balance of evidence leans positive for the next two to six weeks. Conviction is medium: the stock has outpaced the S&P 500 but trails its healthcare sector. A breakout above $235.00 offers only 1.8 to 1 on the second target, short of the 3 to 1 that makes it worth the risk.
The only recent company event in the record is a Form 8-K that STE filed on October 13, 2026, disclosing under Item 1.01 the entry into a material agreement. SEC EDGAR carries no financial terms and no description of the counterparty or purpose. A filing with nothing in it gives the market nothing to price, so it cannot account for the recent move. The stock is up 10.9% over a month, and no news explains that.
The sector explains more. Over the past month XLV, the healthcare sector fund, is up 10.9%, almost exactly the stock's gain, while the S&P 500 is down 2.1%. Over the last five days STE rose 1.2% while the market fell 2.1%, so it held up in a weak tape. But XLV rose 2.8% in the same stretch, which leaves STE 1.6 points behind its sector. Today followed the same pattern: STE fell 0.8% while the market rose 0.2% and XLV slipped 0.2%. The stock is riding a strong sector tide, not leading it.
There are no articles in the debate feed for STE, so there is no sourced bull or bear argument to quote. The price history shows the argument. The bullish side points to a stock that has led the S&P 500 by 7.2% over 50 days, sits above both its 50-day average ($219.61) and 200-day average ($224.36), and carries a consensus buy rating. The cautious side points to a stock that is still down 8.8% for the year while the S&P 500 is up 10.5% and XLV is up 19.0%, that lags XLV by 1.3% over 50 days, and that sits 13.8% below its 52-week high of $268.65. The recent rally looks more like a recovery inside a larger pullback than a finished turn.
On valuation, seven analysts rate the stock a buy with a mean price target of $260.71, which puts the shares 11.2% below it. The targets run from $232.00 to $275.00. The lowest target is barely above today's price, so even the most cautious analyst sees little downside from here. At a market value of about $22.6 billion, the stock is priced for steady execution, not for a surprise.
The long-term thesis is intact but not fully repaired. Price is above its 40-week average, and the 6-month gain is 7.9%, so the larger trend is up. The year-to-date loss and the distance from the high show the stock is still in the recovery phase of a pullback, not in a new leg higher. The 200-day average at $224.36 and the 50-day at $219.61 are now both below price, which is the first condition for that recovery to hold.
For the next two to six weeks, the balance of evidence leans positive, with medium conviction: two of four points. The daily trend runs with the weekly uptrend, and the stock leads the S&P 500 over 50 days. Those two points carry the reading. The relative-strength test against XLV fails, and the reward-to-risk math from the breakout level does not reach the 3 to 1 standard, which is why conviction stops at medium.
The strongest case against is the volume and the calendar. Volume today ran 46.4% below its 20-day average, so the latest push toward $233.35 on November 2 came with little participation. The stock also lags its sector, and a sector-led rally can fade when the sector pauses. RSI near 65 leaves less room before the stock looks stretched, and earnings arrive tomorrow. None of this turns the trend, since price is above every major average, but it is why this is a medium reading and not a high one.
The structure holds above $227.49, a swing zone and the first place a pullback would show damage. Just beneath it sits the round $225.00, and below that the 200-day average at $224.36. The trend itself ends below $219.61, the 50-day average. A break of that level would put the stock back under the average that has supported the recovery. After that, $215.20 and $207.14 are the next swing zones.
The breakout level is a daily close above $235.00 on volume above its 20-day average. Volume matters because today's session showed the opposite. From $235.00 the first target is $240.86, worth 0.7 to 1, and the second is $251.03, worth 1.8 to 1. The stop is $226.06, which is $227.49 less a quarter of the 14-day average range. A close back below that level would mean the breakout failed. The math does not reach 3 to 1. It would take a target beyond the $256.30 swing zone, or an entry closer to the stop, to get there.
The level is $219.61, the 50-day average, and the rule is a weekly close below it. That would break the structure the positive reading depends on. The non-price fact that could do it is tomorrow's earnings report, if the company's outlook for the year comes in weaker than the market expects. That would hit a stock that already trails its sector and is 13.8% below its high.
Interactive STE chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs